【摘 要】
：
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreate
【机 构】
：
Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/C
论文部分内容阅读
Objective: Apatinib is an oral TKI targeting VEGFR-2. Single-agent apatinib treatment has been shown to produce an objective response in patients with pretreated mBC. Oral vinorelbine also holds promise as a treatment of choice in patients with mBC. This study aimed to investigate the efficacy and safety of the oral vinorelbine-apatinib combination in patients with pretreated mBC. In addition, we detected gene variants in ctDNA to explore the therapeutic implications. Methods: This study enrolled patients with HER2-negative mBC who were pretreated with anthracycline/taxanes. Patients were treated with apatinib at 500 mg/425 mg daily plus oral vinorelbine 60 mg/m2 on days 1, 8, and 15 of every cycle (3 weeks). The primary endpoint was PFS. The secondary endpoints were ORR, CBR, OS, and safety. Patients eligible for ctDNA detection were evaluated before and during treatment. Results: Forty patients were enrolled. The median PFS was 5.2 months (95％ CI, 3.4–7.0 months), and the median OS was 17.4 months (95％ CI, 8.0–27.0 months). The ORR was 17.1％ (6/35), and the CBR was 45.7％ (16/35). The most common AEs included gastrointestinal reaction, myelosuppression, and hypertension. In 20 patients, ctDNA was detected at baseline and during treatment. A significant difference was found in PFS for undetected vs. detected baseline ctDNA (13.9 months vs. 3.6 months, P = 0.018). Conclusions: All-oral therapy with apatinib plus vinorelbine displayed objective efficacy in patients with heavily pretreated HER2-negative mBC, with acceptable and manageable toxicity profiles. Patients with no gene variant detected and lower variant allele frequencies in ctDNA at baseline showed longer PFS.
其他文献
目的:研究瑞舒伐他汀对急性冠脉综合征患者择期经皮冠状动脉介入治疗(PCI)术后心功能、心肌损伤标志物的影响。方法:选择2018年5月~2019年5月本院收治的200例急性冠脉综合征择期实施PCI术患者作为研究对象,按照随机数字表法将其分为观察组和对照组,各100例。对照组在常规药物基础上予以辛伐他汀片治疗,观察组在常规药物基础上予以瑞舒伐他汀钙片治疗,两组均治疗6个月。比较两组治疗前和治疗后心功能[左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]、心肌损伤标志
目的:分析本院药品不良反应(ADR)发生的特点及规律,为临床合理用药提供参考.方法:收集本院2018年1月～2019年12月上报国家药品不良反应监测中心的374例ADR报告,按ADR报告的数量
Objective: Natural extracts, including nobiletin, have been reported to enhance the efficacy and sensitivity of chemotherapeutic drugs. However, whether and how
Objective:Several reports have proposed that lnc RNAs,as potential biomarkers,participate in the progression and growth of malignant tumors.HIF1 A-AS2 is a novel lnc RNA and potential biomarker,involved in the genesis and development of carcinomas.However
Objective:The proportion of patients with stageⅠlung adenocarcinoma(LUAD)has dramatically increased with the prevalence of low-dose computed tomography use for screening.Up to 30%of patients with stageⅠLUAD experience recurrence within 5 years after curat
Objective: The systemic inflammation index and body mass index (BMI) are easily accessible markers that can predict mortality. However, the prognostic value of
Objective:Breast cancer was the most common cancer and the fifth cause of cancer deaths among women in China in 2015.The evaluation of the long-term incidence and mortality trends and the prediction of the future burden of breast cancer could provide valu
Objective:Chemotherapy-induced nausea and vomiting(CINV)are common with doxorubicin-cyclophosphamide(AC)chemotherapy.Recommended antiemetic regimens incorporate neurokinin-1 receptor antagonist(NK1 RA),5-hydroxytryptamine type-3 receptor antagonist(5 HT3
虚拟现实(virtual reality,VR)是以计算机技术为核心,生成与一定范围真实环境在视、听、触感等方面近似的数字化环境,是人类在探索自然、认识自然过程中创造产生、逐步形成的一种用于认识自然、模拟自然,进而更好地适应和利用自然的科学方法和技术[1]。目前,VR技术广泛运用于军事、航空航天,公共安全、工业设计、医学、规划、交通、文化教育等行业和部门[2],该技术具有以下三个基本特征:沉浸感(immersion)、交互性(interaction)和构想性(imagination)。
Objective: In some patients with adenomatous polyposis, an identifiable pathogenic variant of known associated genes cannot be found. Researchers have studied t